Abdel-Aleem H, Abol-Oyoun el-S M, Shaaban M M, el-Saeed M, Shoukry M, Makhlouf A, Salem H T
Department of Obstetrics and Gynecology, Assiut University Hospital, Egypt.
Contraception. 1996 Nov;54(5):281-6. doi: 10.1016/s0010-7824(96)00180-1.
Uniplant is a single contraceptive implant intended for one year use. It contains the progestogen nomegestrol acetate. The clinical performance and the effect of its use during the first postpartum year on breastfeeding performance and growth and health of the infants were studied and compared to the findings in a parallel group who used an intrauterine contraceptive device (IUD) in a prospective, non-randomized study. This was carried out in Assiut, Egypt. Two-hundred-forty fully breastfeeding mothers asking for initiation of contraception early postpartum were assigned according to their choices into either nomegestrol subdermal contraceptive implant (Uniplant) (120 women) or intrauterine contraceptive device (CuT 380A) (120 women). The mother and infant pairs were followed up at monthly intervals during the first three months and at two-month intervals thereafter up until the first birthday of the baby. No pregnancy occurred in the two groups. Amenorrhea was significantly more prolonged in the Uniplant group than in the IUD group. There were no significant differences in net continuation rates between the two groups (88.3 versus 92.4 per 100 women, respectively). There were no significant differences between the two groups in the number of breastfeeding episodes, time of weaning, and the cumulative rates of full and partial breastfeeding. There were no significant differences between the two groups in infant weight, weight gain per day, or in infant linear growth. There were no significant differences in the incidence of important health problems affecting the infants of the two groups. However, there were seven infant deaths, six of them were in the Uniplant group. Uniplant subdermal contraceptive implants can be offered as a new contraceptive option suitable for nursing mothers.
优妮普兰（Uniplant）是一种单次使用的避孕植入剂，有效期为一年。它含有醋酸诺美孕酮这种孕激素。在一项前瞻性、非随机研究中，对其临床性能以及产后第一年使用时对母乳喂养情况、婴儿生长和健康的影响进行了研究，并与使用宫内节育器（IUD）的平行组研究结果进行了比较。该研究在埃及阿斯尤特进行。240名要求在产后早期开始避孕的纯母乳喂养母亲根据自己的选择被分为醋酸诺美孕酮皮下避孕植入剂组（优妮普兰组，120名妇女）或宫内节育器组（铜T 380A组，120名妇女）。母婴对在头三个月每月随访一次，此后每两个月随访一次，直至婴儿满一岁。两组均未发生妊娠。优妮普兰组的闭经时间明显长于宫内节育器组。两组的净持续率无显著差异（分别为每100名妇女88.3和92.4）。两组在母乳喂养次数、断奶时间以及纯母乳喂养和部分母乳喂养的累积率方面无显著差异。两组在婴儿体重、每日体重增加或婴儿线性生长方面无显著差异。两组中影响婴儿的重要健康问题发生率无显著差异。然而，有7例婴儿死亡，其中6例在优妮普兰组。优妮普兰皮下避孕植入剂可作为一种适合哺乳期母亲的新避孕选择。
